← Evidence map

ArticleJournal of thoracic disease2026

Induction therapy of pralsetinib followed by conversion surgery for unresectable locally advanced non-small cell lung cancer with the rearranged during transfection (RET) fusion gene mutation: protocol for a single-arm phase II prospective trial (the SALVAGE-P trial).

Han-Yu Deng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Induction therapy of pralsetinib followed by conversion surgery for unresectable locally advanced non-small cell lung cancer with the rearranged during transfection (RET) fusion gene mutation: protocol for a single-arm phase II prospective trial (the SALVAGE-P trial). | OpenQuestion